Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.7 HKD | -2.16% | +14.33% | -17.11% |
04-30 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
04-29 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Analyst Reco.